

derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion, to ii) Keyhole Limpet Hemocyanin;

- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
 - c) a pharmaceutically acceptable carrier;
- the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in a subject, wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a ceramide-derived carbon of the ganglioside derivative to Keyhole Limpet Hemocyanin.--)

- 41 cont
- 79. (New) The composition of claim 78, wherein in the conjugate the ceramide portion comprises a sphingosine base, and the Keyhole Limpet Hemocyanin comprises an e-aminolysyl group, and the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the e-aminolysyl group of Keyhole Limpet Hemocyanin.--
 - 80. (New) The composition of claim 78, wherein the ganglioside derivative is a derivative of GM2.--
 - 81. (New) The composition of claim 78, wherein the ganglioside derivative is a derivative of GD2.--
 - 82. (New) The composition of claim 78, wherein the saponin is QS21.--
 - 83. (New) The composition of claim 78, wherein the amount of the conjugate is an amount between about 1 ug and about 200 ug.--

--84. (New) The composition of claim 83, wherein the amount of the conjugate is an amount between about 50 ug and about 90 ug.

--85. (New) The composition of claim 84, wherein the amount of the conjugate is about 70 ug.--

--86. (New) The composition of claim 83, wherein the amount of the conjugate is an amount between about 1 ug and about 10 ug.--

--87. (New) The composition of claim 84, wherein the amount of the conjugate is about 7 ug.--

--88. (New) The composition of claim 78, wherein the amount of the saponin is an amount between about 1 ug and about 100 ug

--89. (New) The composition of claim 88, wherein the amount of the saponin is about 100 ug.--

--90. (New) The composition of claim 88, wherein the amount of the saponin is about 200 ug.--

--91. (New) The composition of claim 78, wherein the molar ratio of the ganglioside derivative to Keyhole Limpet Hemocyanin is between about 200 and about 1400.--

--92. (New) A method of stimulating or enhancing antibody production in a subject which comprises administering to the subject an effective amount of a composition which comprises:

- a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion, to ii) Keyhole Limpet Hemocyanin;

Sub
H1
Cont

SVB
K 2

b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

c) a pharmaceutically acceptable carrier;--
the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject,
wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a ceramide-derived carbon of the ganglioside derivative to Keyhole Limpet Hemocyanin, so as to thereby stimulate or enhance antibody production in the subject.--

--93.

(New) A method of preventing relapse of a cancer in a subject which comprises administering to the subject an effective cancer relapse preventing amount of a composition which comprises:

a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion, to ii) Keyhole Limpet Hemocyanin;

b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

c) a pharmaceutically acceptable carrier;
the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject,

wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a ceramide-derived carbon of the ganglioside derivative to Keyhole Limpet Hemocyanin, so as to thereby prevent relapse of a cancer in the subject.--

--94.

(New) A method of preventing or treating a cancer in a subject which comprises administering to the subject an effective cancer preventing or treating amount of a composition which comprises:

- Sub J2
- a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion, to ii) Keyhole Limpet Hemocyanin;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmaceutically acceptable carrier;
- the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject, wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a ceramide-derived carbon of the ganglioside derivative to Keyhole Limpet Hemocyanin, so as to thereby prevent or treat a cancer in the subject.--
- H1 cont

- 95. (New) The method of claim 93 or 94, wherein the cancer is of epithelial origin.--
- 96. (New) The method of claim 93 or 94, wherein the cancer is of neuroectodermal origin.--
- 97. (New) The method of claim 96, wherein the cancer of neuroectodermal origin is a melanoma.--
- 98. (New) The method of any one of claims 92-94, wherein the administering is effected at two or more sites.--
- Sub J3
- 99. (New) The method of claim 95, wherein the administering is effected at three sites.--

Remarks:

Claims 53-77 were pending in the subject application. Applicants